vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

NEXT STORY
GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results
PREV STORY
Treace Announces New ALIGN3D™ Data at the 2021 AOFAS Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

NEXT STORY
GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results
PREV STORY
Treace Announces New ALIGN3D™ Data at the 2021 AOFAS Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

GeoVax to Present at World Vaccine & Immunotherapy Conference

author_avatar
NASDAQ Market News

Pfizer and BioNTech Announce Collaboration with Biovac to Manufacture and Distribute COVID-19 Vaccine Doses within Africa

author_avatar
NASDAQ Market News

CoImmune, Inc. Announces FDA Approval of its IND Application to Conduct a Phase 2b Clinical Trial with CMN-001 in Advanced RCC Patients

author_avatar
NASDAQ Market News